PressAugust 25, 2023 Canadian Survey Shows People Aren’t Talking to Doctors About Medical Use of Psychedelics
PressAugust 25, 2023 Sunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy
PressAugust 24, 2023 Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD
PressAugust 24, 2023 Core One Labs : Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions
PressAugust 24, 2023 MindBio Therapeutics Corp. Begins Dosing Mb22001 in Phase 2 Clinical Trial in World’s First Take-Home Microdosing Study in Patients with Depression
PressAugust 24, 2023 Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB)
PressAugust 23, 2023 GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
PressAugust 22, 2023 Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
PressAugust 21, 2023 Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement
PressAugust 17, 2023 Novel Combination of Oral Ketamine and Aspirin Is Safe Form of Pain Medication after Total Knee Replacement Surgery
PressAugust 17, 2023 COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
PressAugust 15, 2023 Filament Health and Nasdq-Listed SPAC Jupiter Acquisition Corp. Announce Filing of SEC Registration Statement
PressAugust 14, 2023 Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
PressAugust 14, 2023 NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain
PressAugust 11, 2023 Apex Labs announces the appointment of Chief Medical Officer & Chief Commercial Officer
PressAugust 11, 2023 atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
